twinter11 - here is the text NEW YORK – Liquid
Post# of 144714
NEW YORK – Liquid biopsy firm Creatv MicroTech is developing a diagnostic platform that measures the amount and size of specific circulating stromal cells called cancer-associated macrophage-like cells (CAMLs) to identify traces of cancer in a patient's bloodstream.
The Potomac, Maryland-based company initially plans to commercialize the method, called LifeTracDx, to predict immunotherapy response in stage II to III non-small cell lung cancer (NSCLC) cancer patients.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)